Quercetin Phytosome® Chronic Fatigue Symptoms

Not Applicable

Completed

• Conditions: Chronic Fatigue Symptoms; Sleep; Physical Performance; Body Composition
• Interventions: Dietary Supplement: Placebo group; Dietary Supplement: Quercetin group

• Registration Number: NCT05730660
• Lead Sponsor: Azienda di Servizi alla Persona di Pavia

Brief Summary

The purpose of this study is to evaluate whether a 3-month period of quercetin supplementation (500 mg of Quercetin Phytosome®) is useful in the treatment of chronic fatigue, as assessed by the Fatigue Impact Scale (FIS-40). Secondary end points are sleep assessment through Pittsburgh Sleep Quality Index (PSQI) and muscle performance assessment through the Short Physical Performance Battery (SPPB) and body composition assessment using DXA.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-09-01
• Primary Completion: 2022-12-31
• Study Completion: 2023-01-31
• Status Verified: 2023-02
• Study First Submitted: 2023-02-07
• Study First Submitted QC: 2023-02-07
• Study First Posted: 2023-02-16
• Last Update Submitted: 2024-08-02
• Last Update Posted: 2024-08-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

• age ≥ 18 years old
• Chronic fatigue symptoms recorded using a self-reported fatigue score assessed using the validated Fatigue Impact Scale (FIS- 40) that comprised chronic tiredness impacts related to physical, cognitive and psychosocial functions.

Exclusion Criteria

• Patients with any active medical condition that explains chronic fatigue (untreated hypothyroidism, sleep apnea, narcolepsy, drug side effects, and iron deficiency anemia)
• Previous diagnosis not unequivocally resolved (chronic hepatitis, malignant tumors)
• Past neuropsychiatric disorders or current severe depressive disorder with psychotic or melancholy features, bipolar disorder, schizophrenia, delusional disorder, dementia, anorexia nervosa, bulimia nervosa
• Participation in another clinical trial of the same or different nature within 30 days prior to inclusion in the study
• Failure to provide signed informed consent
• Consumption of certain drugs/supplements that could affect outcome measures in the past 90 days or whose discontinuation could be a significant problem
• Anticoagulant treatment
• Pregnancy or breastfeeding
• Smoking, alcohol or substance abuse
• Obesity (BMI > 30 kg/m²)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo group	Placebo group	-
Intervention group	Quercetin group	-

Primary Outcome Measures

Name	Time	Method
chronic fatigue symptoms	At baseline and after 3 months	The primary outcome is the change in self-reported fatigue scores assessed using the Fatigue Impact Scale (FIS-40). The FIS-40 comprises 40 items divided into three domains (cognitive, physical, and psychosocial), each item scored from 0 (no fatigue) to 4 (severe fatigue). The total score ranges from 0 to 160, with higher scores indicating worse fatigue.

Secondary Outcome Measures

Name	Time	Method
Sleep quality	At baseline and after 3 months	Sleep disturbances are assessed using the 19-item self-administered Pittsburgh Sleep Quality Index (PSQI) questionnaire. Scores are obtained on each of the seven sleep quality domains: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, sleeping pills, and daytime dysfunction. Each component is rated from 0 to 3 (0 = no sleep problems and 3 = severe sleep problems). The overall PSQI score ranges from 0 to 21 points, with scores ≥5 indicating worse sleep quality
Body composition	At baseline and after 3 months	Body composition is assessed using the dual X-Ray absorptiometry (DXA)
Physical performance	At baseline and after 3 months	Physical performance is assessed using the Short Physical Performance Battery test
Life quality	At baseline and after 3 months	Quality of life is assessed using the Short-Form 12-Item Health Survey (SF-12), a short and generic measure of health status that reproduces the 2 summary scores of the SF-36. The summary of the physical component score and the summary score of the mental component, addressing eight health domains (physical functioning, physical role, body pain, general health, vitality, social functioning, emotional role, and mental health). Each domain is scored separately, and the total scores for the physical and mental components range from 0 to 100, with higher scores indicating better health-related quality of life.

Trial Locations

Locations (1)

l'Istituto di Riabilitazione e cura "Santa Margherita" di Pavia, Azienda di Servizi alla Persona (ASP).; 🇮🇹 Pavia, Italy